What is Respiratory Delivery Systems?
Respiratory Delivery Systems Inc. (RDS) occupies a critical niche in the respiratory health sector, focusing on the development and commercialization of high-efficacy spacer and chamber devices. Their flagship products, the MicroChamber and MicroSpacer, address the persistent challenges of medication delivery for patients suffering from asthma and chronic obstructive pulmonary disease (COPD). By prioritizing portability, ease of maintenance, and universal usability, RDS bridges the gap between complex clinical requirements and patient-centric home care. The company serves a diverse demographic, ranging from pediatric patients to the elderly, while maintaining strong alignment with pulmonologists and asthma educators who prioritize adherence and therapeutic outcomes.
How much funding has Respiratory Delivery Systems raised?
Respiratory Delivery Systems has raised a total of $26K across 1 funding round:
Debt
$26K
Debt (2021): $26K with participation from PPP
Key Investors in Respiratory Delivery Systems
PPP
Public-Private Partnership
What's next for Respiratory Delivery Systems?
With the infusion of $26K, Respiratory Delivery Systems is poised to accelerate its market penetration and operational footprint. The strategic deployment of these funds will likely focus on expanding the reach of their MDI accessory line, potentially through enhanced clinical partnerships and broader healthcare provider adoption. As the company transitions through its current growth phase, the focus remains on optimizing supply chain efficiencies and reinforcing its reputation as a leader in affordable, high-performance pulmonary delivery solutions. Future milestones will likely involve scaling production to meet rising global demand for reliable respiratory support tools, ensuring that RDS remains at the forefront of medical device innovation in the respiratory space.
See full Respiratory Delivery Systems company page
